Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPDCs-T
- Development stage
- Phase 2
- Lead developer
- Senlang Bio
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HPDCs-T is an investigational autologous cellular immunotherapy developed by Hebei Senlang Biotechnology for the treatment of relapsed or refractory Acute Myeloid Leukemia (AML). The therapy utilizes human plasmacytoid dendritic cells (pDCs), a specialized subset of dendritic cells known for their high capacity to produce type I interferons and their potent antigen-presenting abilities. In this therapeutic approach, pDCs are used to prime and activate T cells against tumor-associated antigens. The resulting cell product, containing activated T cells and pDCs, is infused back into the patient to induce a robust anti-leukemic immune response. This strategy leverages both the direct cytotoxic activity of T cells and the immune-modulating effects of pDC-derived cytokines to overcome tumor-induced immunosuppression.
- Other names
- Human Plasmacytoid Dendritic Cell-T cell therapypDC-T cell therapy
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on HPDCs-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPDCs-T.